Sponsors (6)
The bill strengthens allied biodefense coordination, lab safety, and nonproliferation—improving preparedness against biological threats—but does so at the cost of higher taxpayer commitments, potential burdens on scientific collaboration, and ethical/governmental trade‑offs.
U.S. and allied civilians, state and local governments, military and emergency responders gain stronger, coordinated biodefense planning and improved interoperability for detection, attribution, emergency response, and recovery, improving preparedness for biological incidents.
Scientists, researchers, and health systems benefit from elevated safety and security standards across allied research programs, reducing risks of accidental releases and improving laboratory biosafety practices.
Coordinated export‑control policy work among allies reduces the risk that dual‑use biotechnology items are diverted for hostile military or terrorist uses, strengthening nonproliferation.
U.S. taxpayers may face increased costs because expanding NATO biodefense capabilities and coordination likely requires U.S. diplomatic and financial commitments or redirected funds.
Scientists, researchers, and biotech firms could face higher compliance costs and slower legitimate international collaboration due to tighter export controls and coordination.
Emphasizing military-relevant biotechnology research and deployment may raise ethical, proliferation, and public-trust concerns among scientists and the general public.
Based on analysis of 2 sections of legislative text.
Introduced February 23, 2026 by Keith Self · Last progress February 23, 2026
Directs the Secretary of State to expand U.S. cooperation with NATO, major non‑NATO allies, and other partners on biodefense, biosecurity, and biotechnology. It requires the State Department to produce two unclassified strategies (with optional classified annexes) assessing NATO cooperation and international biotechnology/biosecurity cooperation, and to submit the strategies in a report to congressional committees within 270 days of enactment. Requires a follow-up briefing to appropriate congressional committees within 90 days after enactment about significant developments related to the report topics and recent biotechnology or biosecurity events. The work includes coordinating export-control approaches, promoting high safety and security standards for biological research, and evaluating NATO and partner capabilities for detection, attribution, emergency response, and resilience.